Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis.

Liver cirrhosis (LC) is becoming increasingly common among patients presenting with acute coronary syndromes (ACS) and is associated with significant cardiovascular morbidity and mortality. Management of such patients is complicated by LC related complications. Literature is scarce on the safety of antithrombotic regimens and invasive strategies for ACS in patients with LC, especially those undergoing liver transplant evaluation. Recently there has been evidence that cirrhosis is an independent risk factor for adverse outcomes in ACS. As patients with LC are generally excluded from large randomized trials, definitive guidelines for the management of ACS in this particular cohort are lacking. Many antithrombotic drugs require either hepatic activation or clearance; hence, an accurate assessment of hepatic function is required prior to initiation and dose adjustment. Despite a demonstrated survival benefit of optimal medical therapy and invasive revascularization techniques in LC patients with ACS, both strategies are currently underutilized in this population. This review aims to present currently available data and provide a practical, clinically oriented approach for the management of ACS in LC. Randomized clinical trials in LC patients with ACS are the need of the hour to further refine their management for favorable outcomes. © 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Citation

Taha Ahmed, Alla Y Grigorian, Adrian W Messerli. Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2022 Jan;22(1):55-67

Mesh Tags

Substances

PMID: 34050893

search → result